Formuepleje A S Boosts Position in IQVIA Holdings Inc. $IQV

Key Points

• Formuepleje A S increased its IQVIA stake by 29.3% in the second quarter, bringing its holdings to 23,265 shares valued at approximately $4.5 million. Institutional investors collectively own 89.62% of the company.
• IQVIA exceeded quarterly expectations, reporting $3.15 in EPS and $4.37 billion in revenue, with sales up 8.7% year over year. The company issued fiscal 2026 EPS guidance of $12.80–$13.00.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and a $243.62 price target, while insiders sold 15,581 shares worth about $3.8 million over the past three months.

Formuepleje A S raised its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 29.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,265 shares of the medical research company's stock after purchasing an additional 5,278 shares during the period. Formuepleje A S's holdings in IQVIA were worth $4,495,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of IQV. Brighton Jones LLC raised its stake in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock worth $703,000 after acquiring an additional 2,537 shares in the last quarter. Empowered Funds LLC lifted its holdings in shares of IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company's stock valued at $1,715,000 after purchasing an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of IQVIA in the 2nd quarter valued at about $514,000. First Trust Advisors LP grew its stake in IQVIA by 14.8% during the 2nd quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company's stock worth $14,501,000 after buying an additional 11,845 shares during the last quarter. Finally, NewEdge Advisors LLC increased its position in IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company's stock worth $3,582,000 after buying an additional 1,155 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insider Transactions at IQVIA

In other news, insider Keriann Cherofsky sold 558 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the transaction, the insider owned 2,989 shares in the company, valued at $732,932.69. This trade represents a 15.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the firm's stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider owned 1,348 shares of the company's stock, valued at $317,143.96. This trade represents a 57.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 15,581 shares of company stock valued at $3,796,021 in the last three months. Insiders own 1.70% of the company's stock.

IQVIA Trading Down 0.2%

NYSE IQV opened at $267.34 on Monday. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $44.00 billion, a P/E ratio of 33.17, a P/E/G ratio of 2.29 and a beta of 1.18. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $271.80. The firm has a 50-day moving average price of $230.54 and a 200 day moving average price of $192.84.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analysts' expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm's quarterly revenue was up 8.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities research analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

Wall Street Analyst Weigh In

IQV has been the topic of a number of research reports. JPMorgan Chase & Co. raised their target price on shares of IQVIA from $225.00 to $285.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 29th. Royal Bank Of Canada upped their target price on shares of IQVIA from $221.00 to $247.00 and gave the company an "outperform" rating in a report on Wednesday, July 29th. Robert W. Baird raised their price target on IQVIA from $252.00 to $287.00 and gave the stock an "outperform" rating in a report on Wednesday, July 29th. Wall Street Zen cut IQVIA from a "buy" rating to a "hold" rating in a research report on Saturday, August 29th. Finally, Barclays reaffirmed an "overweight" rating on shares of IQVIA in a research note on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $243.62.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.